Summary
The serotonin 5-hydroxytryptamine receptor antagonist ramosetron reduces symptoms significantly more than placebo in women with diarrhea-predominant irritable bowel syndrome. Ramosetron is effective in women at half the dose required to reduce symptoms in men and has a manageable side effect profile.
- ramosetron
- irritable bowel syndrome with diarrhea
- serotonin 5-hydroxytryptamine receptor antagonist
- women
- quality of life
- gastroenterology clinical trials
- irritable bowel syndrome
- NCT01736423
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.